Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review

Date: November 7, 2017
Pages: 21
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U591585A9F9EN
Leaflet:

Download PDF Leaflet

Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review
Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Urigen Pharmaceuticals Inc (Urigen) is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on developing innovative products for amelioration of urethritis, painful bladder syndrome (PBS), nocturia and over active bladder (OAB). Its pipeline includes its flagship candidate, URG101, being developed for the painful bladder syndrome/interstitial cystitis. The company licensed URG101, is a proprietary combination therapy for the relief of pain of bladder. Its other product candidate, URG501, is in pre-clinical development. Urigen is headquartered in North Brunswick, New Jersey, the US.

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Urigen Pharmaceuticals Inc - Key Facts
Urigen Pharmaceuticals Inc - Key Employees
Urigen Pharmaceuticals Inc - Key Employee Biographies
Urigen Pharmaceuticals Inc - Major Products and Services
Urigen Pharmaceuticals Inc - History
Urigen Pharmaceuticals Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Urigen Pharmaceuticals Inc - Business Description
Urigen Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Urigen Pharmaceuticals Inc - Strengths
Urigen Pharmaceuticals Inc - Weaknesses
Urigen Pharmaceuticals Inc - Opportunities
Urigen Pharmaceuticals Inc - Threats
Urigen Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Urigen Pharmaceuticals Inc, Recent Deals Summary

SECTION 4 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Urigen Pharmaceuticals Inc, Key Facts
Urigen Pharmaceuticals Inc, Key Employees
Urigen Pharmaceuticals Inc, Key Employee Biographies
Urigen Pharmaceuticals Inc, Major Products and Services
Urigen Pharmaceuticals Inc, History
Urigen Pharmaceuticals Inc, Key Competitors
Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Urigen Pharmaceuticals Inc, Recent Deals Summary

LIST OF FIGURES

Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Urigen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Halozyme Therapeutics Inc
Janssen Pharmaceuticals Inc
Mission Pharmacal Company
Plethora Solutions Holdings Plc
rEVO Biologics Inc
Riot Blockchain Inc
Telesta Therapeutics Inc
Skip to top


Ask Your Question

Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: